**Table D-60. Evidence table for studies addressing management of PPH (Chauleur 2008b)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Study** **Description** | **Intervention** | **Inclusion/Exclusion** **Criteria & Population** | **Outcomes** |
| Author:Chauleur et al., 200861Country:FranceEnrollment period: 1996 to 2005Birth setting: HospitalFacility characteristics: Tertiary careFunding: NRDesign: Case series | **Intervention:** Women with a primary PPH resistant to medical treatment who underwent uterine artery embolization or hysterectomy.**Groups:****G1a:** embolization**G1b:** hysterectomy**G1c:** embolization & hysterectomyN: **G1a:** 41**G1b:** 6**G1c**: 5Duration of treatment: NRTiming of treatment: NROrder of treatment: NRLength of follow-up:NR, follow-up interview in 2007 | **Operational definition of PPH:** Greater than 500 mL**Definition of success of treatment**: cessation of external bleeding**Method of blood loss measurement:** collecting bag**Severity: NR**Inclusion criteria: * Women with a primary PPH resistant to medical treatment who underwent uterine artery embolization or hysterectomy

Exclusion criteria: NR**Maternal age, yrs, median (range):** **Overall:** 27.3 (19-41)**G1a:** 29.2 ± 4.65**G1b:** 30.1 ± 4.11**G1c:** 36.6 ± 4.56**Parity, n (%):** Primiparous**G1a:** 9 (21.9)**G1b:** 2 (33)**G1c:** 0Multiparous**G1a:** 32 (78)**G1b:** 4 (66)**G1c**: 5 (100)**Weeks gestation:** NR**Single pregnancy, n:****G1a:** 36**Multiple pregnancy, n:****G1a:** 10**Race/ethnicity:** NR**BMI:** NR**Baseline hemoglobin:** NR**SES:** NR**Mode of birth, n (%):** Unassisted vaginal delivery**G1a:** 9 (21.9)**G1b:** 2 (33)**G1c**: 0Instrumental vaginal**G1a:** 2(4.8)**G1b:** 0**G1c**: 0Cesarean**G1a:** 30 (73.1)**G1b:** 4 (66)**G1c:** 5 (100)**Risk factors, n (%):** NR**Primary etiology of PPH, n (%):** Atony**G1a:** 32 (69.5)Placenta accreta or percreta**G1a:** 8 (17.3)Placenta previa**G1a:** 3 (6.5)Placental abruption**G1a:** 1 (2)Myoma and atony**G1a:** 1 (2)Parametrical dissecting hematoma**G1a:** 1 (2)Time between delivery & procedure, min (range)**G1a:** 263 (90-750) | **Mortality:G1a:** 1 (treated with in situ methotrexate and died 4 months after embolization due to methotrexate-related nephrotoxicity**Uterine preservation:**Embolization successful, n (%)**G1a:** 41/46 (89.1)Five patients underwent additional procedures1. parametrical dissecting hematoma, embolization completed by the insertion of a coil into the R uterine artery (G1c)2. Ovarian artery embolization3. Hypogastric artery catheterized & embolization performed beyond the gluteal artery.4. Superselective embolization of the internal iliac artery branch5. Embolization performed after ligation of hypogastric arteries (embolization of the residual stump of hypogastric artery & anastomatic pelvic trats).Future fertility (data for 37/41)No wish for further children: 16No present wish for another child: 5Wanted another child: 16 (39%)Became pregnant within 1-11 months: 16/16 (100%)Return of normal menses**G1a:** 41 (100%)More than 1 pregnancy after embolization: 6Repeat PPH - 1**Harms of intervention:**Allergy to iodine, n **G1a:** 1Acute pulmonary edema, n **G1a:** 1Cardiovascular instability**G1a:** 1Major hemoperitoneum related to dissection of epigastric artery (re-operated 4 times), n**G1a:** 1**Confounders:** NR **Effect modifiers:** NR   |